|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Pliant_Therapeutics
gptkb:Horizon_Pharma
gptkb:CureDuchenne_Ventures
gptkb:Alder_BioPharmaceuticals
gptkb:Madrigal_Pharmaceuticals
Kite Pharma
|
|
gptkbp:advertising
|
gptkb:Mr._John_Doe
gptkb:Dr._David_H._H._Hsu
gptkb:Dr._Jennifer_L._Smith
|
|
gptkbp:awards
|
Best Places to Work
Top 100 Biopharma Companies
Innovative_Company_of_the_Year
|
|
gptkbp:CEO
|
gptkb:Tim_Walbert
|
|
gptkbp:clinicalTrials
|
ongoing
Phase 1
Phase 2
Phase 3
collaborative studies
patient-centered outcomes
biomarker_discovery
|
|
gptkbp:employeeCount
|
over 1,000
|
|
gptkbp:focus
|
rare diseases
|
|
gptkbp:founded
|
2008
|
|
gptkbp:global_presence
|
gptkb:Asia
gptkb:North_America
Europe
|
|
gptkbp:headquarters
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Horizon Therapeutics
|
|
gptkbp:investmentFocus
|
clinical trials
biotechnology startups
healthcare_innovation
|
|
gptkbp:market
|
$4 billion (2023)
|
|
gptkbp:notableFeature
|
gptkb:Krystexxa
Ravicti
Tepezza
|
|
gptkbp:partnerships
|
gptkb:Amgen
Sanofi
AbbVie
|
|
gptkbp:patentType
|
2019
2020
2021
|
|
gptkbp:philanthropy
|
community support
patient advocacy
research funding
|
|
gptkbp:research_focus
|
autoimmune diseases
inflammatory diseases
metabolic diseases
|
|
gptkbp:revenue
|
$1.5 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:sustainability_initiatives
|
diversity and inclusion
employee well-being
environmental responsibility
|